Investors

As a late clinical-stage biopharmaceutical company focused on oncology, our business model is to in-license novel compounds, develop them through clinical stages, and then seek to commercialize them through out-licensing arrangements with biotechnology and pharmaceutical companies or evaluating, on a case-by-case basis, the commercialization of our therapeutic candidates independently.

The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.  APHEXDA® (motixafortide) was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous transplantation for multiple myeloma patients, has reported positive results from a pre-planned pharmacoeconomic study in the U.S., and has had its NDA submission accepted by the FDA with an assigned PDUFA date of September 9, 2023.read more

Upcoming Events View all

There are currently no events to display.
Corporate Presentation

I.R. Contacts

John Lacey, MS, MBA
Head of Corporate Communications & Investor Relations
+1-781-392-5514
IR@BioLineRx.com